Allie LogoA Search Service for Abbreviation / Long Form

■略語／展開語 : ROMO／Romosozumab

関連PubMed/MEDLINE情報

合計出現文献数:

21

略語:

ROMO

(

>>共起略語

)

展開形:

Romosozumab

(ヒト化抗スクレロスチン抗体;骨粗鬆症治療) ロモソズマブ

ROMO (21)回

romosozumab (18)回

Romosozumab (3)回

ROMO / romosozumab (18)回

ROMO / Romosozumab (3)回

No.
発表年
題目
共起略語

1

2025

BMD, BP, Dmab, FN, LS, TH, TPTD

2

2025

AFF, BP, Dmab, ONJ

3

2025

OVF, VCR

4

2025

AOM, Dmab, MPR, TPTD

5

2025

Impact of prior teriparatide treatment on the effectiveness of romosozumab in patients with postmenopausal osteoporosis: A case-control study.
BMD, LS, TH, TPTD

6

2024

An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case-control study.
ACPA, BMD, CDAI, HAQ-DI, LS, RA

7

2024

Comparison of efficacy of romosozumab with denosumab and risedronate in patients newly initiating glucocorticoid therapy.
BMD, BP, Dmab, GIOP

8

2024

Romosozumab versus denosumab in long-term users of glucocorticoids: A pilot randomized controlled trial.
BMD, DEN, GC

9

2024

Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?
ABL, BMD, PTH1R, TPTD

10

2024

The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women with Osteoporosis.
BMD, DXA, FN, LS, TH, TPTD

11

2023

Efficacy of Three Teriparatide Preparations and Romosozumab, Osteogenesis Promoters, in the Treatment of Fresh Vertebral Fractures: A Retrospective Observational Study.
DTPD, TPD

12

2022

Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis.
BMD, FN, LS, PINP, TH

13

2022

Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis.
BMD, BP, Dmab, LS, TH, TPTD

14

2022

Importance of Time Point-Specific Indirect Treatment Comparisons of Osteoporosis Treatments: A Systematic Literature Review and Network Meta-Analyses.
ABL, ALN, BMD, DEN, IB, NMAs, RCTs, RIS, RLX, TPTD, ZOL

15

2022

One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study.
BMD, DENO, FN, HD, LS, TH

16

2021

Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients.
BMD, BP, DENO, ND

17

2021

Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis.
BMD, BP, LS, TH, TPTD

18

2020

Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis.
BMD, BP, FN, LS, TPTD

19

2020

Romosozumab (sclerostin monoclonal antibody) for the treatment of osteoporosis in postmenopausal women: A review.
BMD, FDA, FRAME, RWE

20

2019

Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis.
ALN, CrI, DEN, FN-BMD, IBN, NMA, RCT, RIS, RLX, TPTD, ZOL

Rows per page:

1–20 of 21